Skip to main content
logotype

Main navigation (without target group)

  • Joint protection
    • Every bleed has an impact
    • Joint damage and QoL for PwH
    • Role of effective prophylaxis
  • Introducing ELOCTA
    • First extended half-life rFVIII
    • Natural pathway for half-life extension
  • Why ELOCTA?
    • Protecting joint health
    • Long-term confidence
    • Improvement of quality of life
    • Summary
    • Clinical trials summary
  • ELOCTA – Safety profile
  • How to use ELOCTA
    • How to dose?
    • Instructions for use
    • Vial sizes and packaging
  • For patients
Why_Elocta_banner

Why ELOCTA?

Why ELOCTA?

Protecting joint health

        

Find out more

Long-term confidence

      

Find out more

Improvement of quality of life

Find out more

Summary

Find out more

Clinical trials summary

Find out more
Image

You are about to enter elocta.com.

Please select if you are a healthcare professional or a patient.

I'm a

Professional
Patient

Footer Menu

  • PATIENT SAFETY
  • PRESCRIBING INFORMATION
  • MEDICAL ENQUIRIES
  • COOKIE POLICY
  • PRIVACY POLICY
  • TERMS OF USE
  • SOBI.COM
sobi

The information on this website is intended for Healthcare Professionals (HCPs) only

© 2020 Swedish Orphan Biovitrum AB (publ) 
All rights reserved  
Sobi and ELOCTA are trademarks of Swedish Orphan Biovitrum AB (publ)
All third party trademarks are the property of their respective owners

Document number: PP-6168
Website updated: 31-01-20

Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm, Sweden 
Reg.No. 556038-9321

TEl: +4686972000

E-mail: medical.info@sobi.com